What is the diagnostic algorithm for hyponatremia, including assessment of severity, plasma osmolality, volume status, urine studies, and appropriate management?

Hyponatremia Diagnostic Algorithm

Initial Assessment and Severity Classification

Begin by measuring serum sodium and immediately assess for severe symptoms—patients with altered mental status, seizures, coma, or respiratory distress require emergent 3% hypertonic saline before completing any diagnostic workup. 1

Symptom-Based Triage

• Severe symptoms (seizures, coma, GCS ≤8, respiratory distress): Administer 3% hypertonic saline immediately, targeting a 5–6 mmol/L rise in the first 6 hours, never exceeding 8 mmol/L total in 24 hours to prevent osmotic demyelination. 1

• Mild-to-moderate symptoms with sodium <120 mmol/L: Transfer to intermediate care, monitor sodium every 4 hours, and complete diagnostic workup before initiating specific therapy. 1

• Asymptomatic with sodium <131 mmol/L: Proceed with full diagnostic algorithm below before treatment. 1

Step 1: Confirm True Hypotonic Hyponatremia

Measure serum osmolality to exclude pseudohyponatremia and translocational hyponatremia. 1, 2

• Serum osmolality ≥280 mOsm/kg: Consider pseudohyponatremia (laboratory artifact, severe hyperlipidemia, hyperproteinemia) or translocational hyponatremia (hyperglycemia—each 100 mg/dL glucose above 100 lowers sodium by ~1.6 mmol/L). 1

• Serum osmolality <275 mOsm/kg: Confirms true hypotonic hyponatremia; proceed to Step 2. 3, 1

Step 2: Measure Urine Studies

Obtain urine osmolality and urine sodium concentration simultaneously. 1, 4

• Urine osmolality <100 mOsm/kg: Suggests primary polydipsia or reset osmostat (rare); kidneys are appropriately diluting urine. 1

• Urine osmolality >100 mOsm/kg: Indicates inappropriate ADH activity or renal sodium losses; proceed to Step 3. 3, 1

Step 3: Clinical Volume Status Assessment

Physical examination is the cornerstone for categorizing hyponatremia, though it has only 41% sensitivity for detecting true hypovolemia. 3 Assess the following:

Hypovolemia Indicators

• Dry mucous membranes, decreased skin turgor, flat jugular veins 1
• Orthostatic hypotension (≥20 mmHg systolic or ≥10 mmHg diastolic drop) 1
• Tachycardia on standing (≥10 bpm increase) 3

Euvolemia Indicators

• Normal skin turgor, moist mucous membranes 1
• No peripheral edema, normal jugular venous pressure 1

Hypervolemia Indicators

• Peripheral edema, ascites, elevated jugular venous pressure 1
• Pulmonary crackles/rales 1

Critical caveat: Physical examination alone misses true volume depletion in 59% of cases. 3 When clinical assessment is equivocal, use urine sodium and consider measuring central venous pressure (CVP <5 cm H₂O confirms hypovolemia; 6–10 cm H₂O suggests euvolemia). 3

Step 4: Integrate Urine Sodium with Volume Status

Hypovolemic Hyponatremia

• Urine sodium <30 mmol/L: Extrarenal losses (vomiting, diarrhea, third-spacing, burns). Treat with 0.9% normal saline until euvolemia restored. 1

• Urine sodium >40 mmol/L: Renal losses. Differentiate:

  • Diuretic use: Most common; discontinue diuretic and replace volume. 3
  • Cerebral salt wasting (CSW): Suspect in neurosurgical patients (post-craniotomy, subarachnoid hemorrhage). Treat with 3% hypertonic saline plus fludrocortisone 0.1–0.2 mg daily for 7 days; never fluid-restrict—this increases cerebral infarction risk from 27/44 to 21/26 patients in one series. 3, 1
  • Adrenal insufficiency: Check morning cortisol (<3 µg/dL confirms; >15 µg/dL excludes; 3–15 µg/dL requires ACTH stimulation test). 1

Euvolemic Hyponatremia (SIADH)

Diagnosis requires: Urine osmolality >100 mOsm/kg, urine sodium >40 mmol/L, clinical euvolemia, and exclusion of hypothyroidism (TSH) and adrenal insufficiency. 3, 1

• Serum uric acid <4 mg/dL has 73–100% positive predictive value for SIADH. 3, 1

• First-line treatment: Fluid restriction to ≤1 L/day, monitoring sodium every 4 hours initially then daily. 1

• Second-line (if fluid restriction fails in ~50%): Tolvaptan 15 mg daily, titrated to 30–60 mg, for short-term use (≤30 days only). 1

Hypervolemic Hyponatremia

Clinical signs: Edema, ascites, elevated JVP; etiologies include heart failure, cirrhosis, nephrotic syndrome. 1

• Urine sodium <30 mmol/L: Typical in untreated heart failure or cirrhosis (avid sodium retention). 1

• Management hierarchy:

  1. Optimize underlying disease (heart failure therapy, cirrhosis management). 1
  2. Combined sodium and fluid restriction to 1–1.5 L/day. 1
  3. Adjust or discontinue diuretics if causing hypovolemia. 1
  4. In cirrhosis with sodium <130 mmol/L:
     • If hypovolemic (from diuretic overuse): Give 0.9% saline to restore volume. 1
     • If hypervolemic: Enforce fluid restriction; reserve hypertonic saline only for severe neurologic symptoms. 1
     • Tolvaptan may be used short-term (≤30 days) for symptomatic or severe hyponatremia with persistent congestion. 1

Step 5: Additional Diagnostic Tests

• Serum uric acid: <4 mg/dL strongly suggests SIADH. 3, 1

• Fractional excretion of urea (FEUrea): <55% predicts saline responsiveness (true hypovolemia) with 71–100% positive predictive value. 3

• Thyroid function (TSH, free T4): Rule out hypothyroidism in euvolemic hyponatremia. 1

• Morning cortisol: Rule out adrenal insufficiency. 1

• Do NOT order: ADH or natriuretic peptide levels—they have no diagnostic value in clinical practice. 1

Special Population: Neurosurgical Patients

Treat hyponatremia even when sodium is 131–135 mmol/L because lower levels increase cerebral vasospasm risk. 3, 1

• Presume cerebral salt wasting until proven otherwise in post-craniotomy or subarachnoid hemorrhage patients. 3, 1

• Key differentiator from SIADH: CSW presents with clinical hypovolemia (orthostatic hypotension, dry mucous membranes) despite high urine sodium >40 mmol/L and high urine osmolality. 3, 1

• Management: 3% hypertonic saline, fludrocortisone, and volume expansion; avoid fluid restriction—it markedly increases cerebral infarction risk. 3, 1

Correction Rate Guidelines

Acute Hyponatremia (<48 hours)

• Rapid correction (>1 mmol/L per hour) is safe because cerebral adaptation is incomplete. 1

Chronic Hyponatremia (≥48 hours)

• Maximum correction: ≤8 mmol/L per 24 hours to prevent osmotic demyelination syndrome (parkinsonism, quadriparesis, death). 1
• After initial 6-hour aggressive phase achieving 6 mmol/L rise, only an additional 2 mmol/L may be added over the remaining 18 hours. 1

Prognostic Data

• In patients with sodium <115 mmol/L, survivors achieved mean sodium of 127.1 mmol/L at 48 hours versus 118.8 mmol/L in non-survivors (P=0.0016), indicating mortality benefit from adequate correction. 1

Common Diagnostic Pitfalls

• Assuming all post-neurosurgical hyponatremia is SIADH: CSW is actually more common and requires opposite therapy (volume expansion vs. fluid restriction). 3, 1

• Relying solely on physical examination for volume status: Sensitivity is only 41%; use urine sodium, fractional excretion of urea, or CVP when uncertain. 3

• Fluid-restricting cerebral salt wasting: This critical error increases cerebral infarction risk; always confirm euvolemia before restricting fluids. 3, 1

• Ignoring hyponatremia in SAH when sodium is 131–135 mmol/L: Treatment is indicated to reduce vasospasm risk. 3, 1

• Over-correcting chronic hyponatremia: Exceeding 8 mmol/L/24 hours causes osmotic demyelination; monitor sodium every 2 hours during active correction. 1